Mayra (Dienogest, Ethinylestradiol)

The formulation contains dienogest, a progestogen, and ethinylestradiol, an estrogen. Together they suppress the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation. They also thicken cervical mucus and alter the endometrial lining, reducing the chance of sperm entry and implantation.

The dosing regimen for Mayra is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily at the same time, but the exact schedule and any missed‑dose instructions should be provided by the prescriber.

Mayra is contraindicated during pregnancy and should not be started in women who are already pregnant. Limited data are available for breastfeeding; therefore, the benefit‑risk balance must be evaluated by a clinician before use in lactating women.

To request Mayra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mayra contains dienogest, which has a higher anti‑androgenic activity than some older progestins such as levonorgestrel. This can result in a different side‑effect profile, particularly regarding acne and weight changes, while offering comparable contraceptive efficacy.

Mayra tablets should be stored at room temperature, below 25 °C, in the original blister pack. Protect them from excess moisture and direct sunlight to maintain product stability throughout the shelf life.

Mayra is taken orally, usually as a single tablet each day. It should be taken at the same time each day to maintain consistent hormone levels and maximize contraceptive effectiveness.

The most serious adverse events include thromboembolic disorders such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. These risks are higher in smokers over 35, women with a history of clotting disorders, or those with uncontrolled hypertension.

Mayra should not be used by women who are pregnant, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, known or suspected breast cancer, or who are smokers aged 35 years or older. Contraindications must be confirmed by a qualified healthcare professional.